The following are your points.
1)Abbott is working WITH Inverness and your failure to comprehend this important symbiotic relationship.
That is a pipe dream if there ever was one. If ABT was was working with Inverness, why did they not do a sublicense at no cost. Truly an absurd speculation.
2)The importance of early detection, and the cost SAVINGS by early treatment.
You have no proof of any cost savings related to RECAF and since RECAF will probably never make it to market, no studies will ever be done.
3)The fact that NO ONE IS SELLING stock when there are thousands of investors in Biocurex that obviously don't share any of your thoughts.
The fact that multiple close out sales have hit the bid proves that statement to be wrong and sellers are closing out their accounts to the last share.
4)Oncopet IS a genious idea and is about to launched.
IMO, oncopet was a pump so employees could sell stock. The next filing will no doubt prove me correct that Moro paid his employees for multiple months. Multiple close out sales occurred the day of the announcement. Someone was sure selling.
5)The ISOBM is around the corner.
And what do you suppose Moro will present this time? My guess is Urine RECAF.
6)Biocurex did not close its doors and file for bankruptcy, on the contrary, we had private investors lined up.
No, Moro began paying for employees and services with stock. That, along with strategic pumps has kept the doors open.
7)Wittenberg stepped down and has sold very FEW shares over a 5 year period (he absolutely did not quit to dump shares).
Wittenberg has definitely resigned and sold shares to be at least below the 5% SEC reporting level. I suspect he has sold a very large amount if not nearly all of his position by now.
8)We will see revenues THIS YEAR.
This company has been in business for well over 8 years and each year has promised sales are about to begin. Nothing has changed.
9)Goshen and Bhlokin continue to provide outside independent data and more patents will continue to secure the technology.
Moro has allowed multiple patent applications to lapse.
Do you know of any company that has not had setbacks only to prove the naysayers were wrong (look at HGSI, DNDN, FUQI, OGXI) all biotech companies and I am aware of many, many more. Why is it so hard to believe that Biocurex WON'T emerge. Hasn't Biocurex been down this road before and the share price went from .05 to 4.00 in a matter of months. Can you say "deja vous?"
And the cow jumped over the moon.
News 
Market Data 
Discover 
